Claims
- 1. A method for in vitro cell culture comprising:
(a) adding a macroscopic membrane which is formed by self-assembly of amphiphilic peptides in an aqueous solution containing monovalent metal cations to a cell culture medium comprising cells, thereby forming a membrane/culture mixture; (b) maintaining the mixture under conditions sufficient for cell growth.
- 2. The method of claim 1 wherein the peptides are greater than 12 amino acids in length, have alternating hydrophobic and hydrophilic amino acids, and are complementary and structurally compatible.
- 3. The method of claim 2 wherein the hydrophilic amino acids are selected from amino acids which can form ionized pairs and amino acids which can form hydrogen bonds.
- 4. The method of claim 1 wherein the peptides are homogeneous.
- 5. The method of claim 1 wherein the macroscopic membrane was formed by self-assembly of a peptide having the sequence (Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys)n, where n is greater than or equal to 2.
- 6. The method of claim 1 wherein the macroscopic membrane formed by a peptide having the sequence (Arg-Ala-Asp-Ala-Arg-Ala-Asp-Ala)n, where n is greater than or equal to 2.
- 7. The method of claim 1 wherein the macroscopic membrane is not substantially affected by a condition selected from the group consisting of:
a) aqueous solution; b) serum; c) ethanol; d) dilution of the peptide; e) concentration of the monovalent metal cations; f) temperature up to 90° C.; g) pH from 1 to about 11; h) up to 10% sodium dodecyl sulfate; i) up to 7 M guanidine hydrochloride; j) up to 8 M urea; and k) active protease.
- 8. The method of claim 7 wherein the aqueous solution is selected from water, a salt solution, and tissue culture medium.
- 9. The method of claim 7 wherein the protease is trypsin, α-chymotrypsin, papain, protease K or pronase.
- 10. The method of claim 1 wherein the cells are mammalian cells.
- 11. The method of claim 1 wherein the cells are human cells.
- 12. A method for forming a macroscopic membrane comprising combining peptides, which are greater than 12 amino acids in length, have alternating nonpolar and hydrophilic amino acids, and are complementary and structurally compatible, with monovalent metal cations in an aqueous solution under conditions suitable for self-assembly of the peptide into the macroscopic membrane.
- 13. The method of claim 12 wherein the peptides are homogeneous.
- 14. The method of claim 13 wherein the peptides have a sequence characterized by (Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys)n, where n is bigger than or equal to 2.
- 15. The method of claim 13 wherein the peptides have a sequence characterized by (Ala-Arg-Ala-Arg-Ala-Asp-Ala-Asp)n, where n is bigger than or equal to 2.
- 16. The method of claim 12 wherein the peptide is chemically synthesized.
- 17. The method of claim 12 wherein the monovalent metal cations are selected from Li+, Na+, and K+.
- 18. The method of claim 12 wherein the peptides are added to an aqueous solution containing the monovalent metal cations.
- 19. The method of claim 18 wherein the aqueous solution is phosphate-buffered saline.
- 20. The method of claim 12 wherein the suitable conditions comprise the absence of an inhibitor of the self-assembly of the peptides into the macroscopic membrane.
- 21. The method of claim 20 wherein the inhibitor is a divalent metal cation.
- 22. The method of claim 20 wherein the inhibitor is sodium dodecyl sulfate.
- 23. The method of claim 12 wherein the suitable conditions comprise a pH of less than 12.
- 24. A method for slow-diffusion delivery of a drug comprising administering the drug in a vehicle comprising a macroscopic membrane formed by self-assembly of amphiphilic peptides.
- 25. The method of claim 24 wherein the peptides have a sequence characterized by (Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys)n, where n is greater than or equal to 2.
- 26. The method of claim 24 wherein the peptides have a sequence characterized by (Ala-Arg-Ala-Arg-Ala-Asp-Ala-Asp)n, where n is greater than or equal to 2.
- 27. The method of claim 24 wherein the drug is administered orally.
- 28. A method for identifying a drug which inhibits the self-assembly of amphiphilic peptides into a macroscopic membrane comprising:
a) combining a drug with the amphiphilic peptides and monovalent metal cations in an aqueous solution under conditions which would be suitable for self-assembly of the amphiphilic peptides into a macroscopic membrane in the absence of the drug; and b) detecting decreased membrane formation, wherein decreased membrane formation in the presence of the drug indicates that the drug inhibits the self-assembly of the amphiphilic peptides into a macroscopic membrane.
- 29. A drug identified by the method of claim 28.
- 30. Substantially pure DNA having all or a portion of the nucleotide sequence of FIG. 12C (SEQ ID NO: 1).
- 31. Substantially pure DNA which encodes a protein having all or a biologically active portion of the amino acid sequence of FIG. 1 (SEQ ID NO: 2).
- 32. Isolated protein having all or a biologically active portion of the amino acid sequence of FIG. 1 (SEQ ID NO: 2).
- 33. A reagent comprising the isolated protein of claim 32, which is a substrate for a protein kinase selected from the group consisting of:
a) CDC28; b) casein kinase II; c) cAMP-dependent protein kinase; d) tyrosine kinase; and e) protein kinase C.
- 34. A reagent comprising the isolated protein of claim 32, which binds left-handed Z-DNA.
- 35. The reagent of claim 34 wherein the protein has a portion of the amino acid sequence of FIG. 1 (SEQ ID NO: 2) from amino acids 306 to 339.
- 36. A reagent which converts B-DNA to Z-DNA comprising a peptide selected from the group consisting of:
a) KAKAK (SEQ ID NO: 29); b) KAK; and c) KAHAK (SEQ ID NO: 30).
- 37. A reagent which converts B-DNA to Z-DNA comprising the peptide KAKAX (SEQ ID NO: 31), where X is any amino acid.
RELATED APPLICATION
[0001] This application is a Continuation-in-Part of U.S. Ser. No. 07/973,326, filed Dec. 28, 1992, which is incorporated herein by reference.
GOVERNMENT FUNDING
[0002] This work was supported by Grant No. NIH-5R37-CA04186 from the National Institutes of Health and by Grant No. N00014-90-J-4075 from the Office of Naval Research. The U.S. Government has certain rights in this invention.
Continuations (2)
|
Number |
Date |
Country |
Parent |
08824515 |
Mar 1997 |
US |
Child |
10390472 |
Mar 2003 |
US |
Parent |
08293284 |
Aug 1994 |
US |
Child |
08824515 |
Mar 1997 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07973326 |
Dec 1992 |
US |
Child |
08293284 |
Aug 1994 |
US |